Commodore Capital News Today

Pharvaris (NASDAQ:PHVS – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Morgan Stanley in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $34.00 price target on the stock. Morgan Stanley’s price objective indicates a potential upside of 64.65% from the stock’s previous […]

ABIVAX Société Anonyme (NASDAQ:ABVX – Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 76,306 shares were traded during trading, a decline of 1% from the previous session’s volume of 76,878 shares.The stock last traded at $14.27 and had previously closed at $13.97. ABIVAX Société Anonyme Stock Performance The company’s 50 day moving […]

Nkarta (NASDAQ:NKTX – Free Report) had its price target increased by Canaccord Genuity Group from $15.00 to $16.00 in a research note published on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the stock. A number of other brokerages have also recently weighed in on NKTX. Mizuho decreased their price objective on […]

Biotech Stock News Bite - Avalo Therapeutics, Inc. (NASDAQ: AVTX) Makes NASDAQ Top Gainers List on News it acquired Phase 2-ready anti-IL-1β mAb

Nkarta, Inc. (NASDAQ:NKTX – Get Free Report)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $11.09, but opened at $10.80. Nkarta shares last traded at $10.82, with a volume of 70,617 shares. Analyst Ratings Changes Several research analysts have recently weighed in on the stock. Canaccord […]

Nkarta, Inc. (NASDAQ:NKTX – Get Free Report)’s share price rose 4.1% during mid-day trading on Wednesday after Canaccord Genuity Group raised their price target on the stock from $15.00 to $16.00. Canaccord Genuity Group currently has a buy rating on the stock. Nkarta traded as high as $10.53 and last traded at $10.27. Approximately 318,359 […]

Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc.Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to

Nkarta (NASDAQ:NKTX – Free Report) had its target price decreased by Mizuho from $31.00 to $25.00 in a report published on Friday morning, Benzinga reports. Mizuho currently has a buy rating on the stock. NKTX has been the subject of a number of other reports. HC Wainwright decreased their price target on Nkarta from $22.00 […]

Needham & Company LLC reaffirmed their buy rating on shares of Viridian Therapeutics (NASDAQ:VRDN – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a $30.00 target price on the stock. Other equities analysts have also issued research reports about the stock. Oppenheimer increased their target price […]

HC Wainwright reiterated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN – Free Report) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $36.00 target price on the stock. HC Wainwright also issued estimates for Dyne Therapeutics’ Q1 2024 earnings at ($0.83) EPS, Q2 2024 earnings at ($0.83) […]